Antimicrobial resistance is now a clinical and economic emergency
Antimicrobial resistance has moved far beyond the familiar frame of a microbiology problem. In this PLOS Medicine Special Issue commentary, the burden is presented as a direct threat to neonatal survival, hospital care, community prescribing, and long-term health system stability. The numbers are stark: drug-resistant infections contributed to an estimated 4.95 million deaths globally in 2019, with the heaviest burden in low- and middle-income countries, especially sub-Saharan Africa. By 2050, annual deaths could climb to 10 million if current trends continue.
The scale matters because AMR is not driven by a single defect in practice. It emerges from antibiotic overuse, weak infection control, poor access to diagnostics, limited sanitation, and the movement of resistant organisms across humans, animals, and the environment. Bacteria exchange DNA with ease, and antibiotic exposure often selects for newly acquired resistance mechanisms rather than stopping transfer altogether. In practical terms, that means every unnecessary prescription can help maintain the ecology in which resistance flourishes.
Neonatal sepsis exposes the sharpest edge of resistance
Newborns sit at the center of the most dangerous clinical consequences. In the NeoOBS global prospective study of neonatal sepsis, spanning 11 countries across four continents, Klebsiella pneumoniae emerged as the most common causative pathogen. Mortality ranged from 10% to 12%, and was higher when blood cultures were positive.
The treatment patterns were just as concerning as the microbiology. More than 200 antibiotic combinations were used across 3,204 neonatal sepsis cases, and prescribing drifted substantially away from WHO-recommended regimens. Colistin and other reserve agents were used frequently. This is not simply a stewardship problem; it is a sign that clinicians are being forced to improvise in settings where resistant pathogens have already outrun the standard empiric playbook.
Neonatal care cannot rely on broad-spectrum escalation alone. When first-line regimens no longer match the local pathogen mix, infants are exposed to delays in effective therapy, unnecessary toxicity, and further pressure for resistance selection. The call for urgent trials of novel empiric antibiotic regimens follows directly from that clinical reality.
Carbapenem-resistant Klebsiella pneumoniae has spread widely in children
The review also draws attention to carbapenem-resistant K. pneumoniae in neonates and children, where the pathogen has become a global concern rather than a regional one. In a systematic review covering more than 120 studies from 30 countries, including 21 LMICs, investigators identified more than 140 sequence types linked to neonatal CRKP infections. Among the three common lineages described, ST17 appeared in eight countries across four continents.
The molecular picture is equally troubling. Among 1,592 neonatal CRKP strains evaluated for carbapenemase-encoding genes, NDM was the most common, found in 64.3% of strains. The pooled mortality due to neonatal CRKP infection reached 22.9%, with a 95% confidence interval of 13.0% to 32.9%.
One sentence captures the bedside consequence plainly: carbapenem resistance in the neonatal unit turns routine empiric therapy into a race against time.
Inappropriate outpatient prescribing starts early and spreads fast
AMR does not begin and end inside hospitals. In the BIRDY mother-and-child cohort across urban and rural sites in Cambodia, Madagascar, and Senegal, pediatric outpatient prescribing was frequently inappropriate. Of consultations resulting in an antibiotic prescription, 76.5% were judged not to require one.
Rhinopharyngitis, gastroenteritis, and uncomplicated bronchiolitis accounted for the largest share of unnecessary use. Children older than 3 months living in rural areas were more likely to receive inappropriate prescriptions. The implication is straightforward: stewardship cannot be confined to tertiary hospitals or national policy statements. It has to reach frontline outpatient care, where viral syndromes and self-limited illness are still being treated as though antibiotics could alter their course.
The review links this prescribing pattern to the broader ecology of resistance in low-resource settings. Inadequate access to water, sanitation, and hygiene, together with limited diagnostics and difficulty obtaining appropriate antibiotics, creates the conditions in which resistant organisms circulate between people, animals, and the environment.
Infant microbiomes carry the price of repeated antibiotic exposure
The infant gut is another critical reservoir. A review of carriage of resistant organisms and resistance genes in children under 2 years found that antibiotics significantly alter the diversity and composition of the gut microbiome in LMIC settings, while also selecting for resistance genes that can persist for long periods. Those findings matter because the gut is not a passive bystander; it is an ecosystem in which antibiotic pressure can reshape microbial communities and leave behind a durable resistance signature.
Methodologic inconsistency remains a major limitation in this field. Studies use heterogeneous designs and sequencing approaches, making it difficult to define the true magnitude of antibiotic-driven microbiome disruption. Even so, the direction of effect is consistent enough to inform policy: repeated early-life antibiotic exposure carries consequences that extend well beyond the treated infection.
Hospital transmission, COVID-19 disruptions, and the cost of inertia
Hospital-associated resistant infections remain a major driver of harm. In a review of 109 studies of bloodstream infections in hospitalized patients from LMICs, several WHO critical and high-priority pathogens were associated with higher mortality, longer stays, ICU admission, and increased cost. The data varied across regions, income groups, and pathogen-drug pairs, but the overall signal was clear: resistance worsens outcomes and consumes resources already in short supply.
Using point prevalence survey data from 99 countries, the annual number of hospital-associated resistant infections caused by high-priority pathogens was estimated at 136 million, with the highest burden in China, Pakistan, and India. These figures are not abstract epidemiology. They represent prolonged admissions, more complex treatment, greater ICU demand, and escalating hospital costs.
During the COVID-19 pandemic, disruption of infection control practices created a natural experiment. Modeling suggested that surges in COVID-19 cases increased colonization by 14% and AMR rates by 10%, while COVID-19 control measures reduced patient acquisition of drug-resistant bacteria by 28%. The lesson is operational rather than theoretical: infection prevention measures can still blunt transmission when they are enforced consistently.
Vaccination, surveillance, and the case for coordinated action
Vaccines will not solve AMR on their own, but they can reduce the infections that lead to antibiotic exposure in the first place. A modeling study of a hypothetical maternal vaccine against K. pneumoniae estimated that it could avert 80,258 neonatal deaths and 399,015 neonatal sepsis cases annually worldwide, preventing more than 3.40% of all neonatal deaths. The largest relative gains were projected in Africa, including Sierra Leone, Mali, and Niger, and in South-East Asia, including Bangladesh, where vaccination could avert more than 6% of neonatal deaths.
Those estimates depend on assumptions, but the biological logic is persuasive. Prevent the bacterial infection early, and the cascade of empiric broad-spectrum treatment, resistance selection, toxicity, and transmission never begins.
The final demand from this Special Issue is unusually concrete: standardized reporting of AMR infections and antibiotic use, stronger diagnostics, and better national, regional, and local surveillance. Without comparable data, stewardship policies remain blunt instruments. With them, clinicians and public health systems can match treatment to resistance patterns instead of guessing.
A September 2024 United Nations high-level meeting will revisit the global response. The stakes are large enough to demand more than general commitments. AMR already exacts a toll larger than tuberculosis, malaria, or HIV/AIDS in annual deaths, and if current trends persist, the economic losses could exceed $100 trillion by 2050. The problem is no longer whether AMR matters. The problem is whether governments, health systems, and funders will build the diagnostics, vaccines, drugs, and surveillance networks needed before resistant infections become even harder to control.